This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Centene Corporation is a well-diversified, multi-national healthcare company that primarily provides a set of services to the government sponsored healthcare programs. The company serves the under-insured and uninsured individuals through member-focused services. It is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Centene is now a $100-billion plus enterprise catering healthcare services to more than 24 million members across 50 states. The recent acquisition of WellCare Health leveraged the company’s position as the largest Medicaid managed care organization in the country. The combined entity now has 22 million members. In 2019, the company retained its market-leading position nationwide, serving 1.8 million exchange members across 20 states at the year-end.
Centene (CNC) Q3 Earnings Beat on Commercial Growth, View Raised
by Zacks Equity Research
Centene (CNC) anticipates adjusted EPS to register a minimum of $6.60 this year.
Compared to Estimates, Centene (CNC) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Centene (CNC) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Centene (CNC) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of 26.58% and 5.13%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Can Centene's (CNC) Q3 Earnings Beat on Membership Growth?
by Zacks Equity Research
Centene's (CNC) third-quarter results are likely to reflect higher premiums and lower cost of services.
Centene (CNC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Centene (CNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold Centene (CNC) in Your Portfolio
by Zacks Equity Research
Robust revenue growth outlook, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.
Why Centene (CNC) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
UnitedHealth Group (UNH) Q3 Earnings Beat, Boosts '23 EPS View
by Zacks Equity Research
UnitedHealth Group's (UNH) management presently forecasts adjusted net EPS between $24.85 and $25.00 for 2023.
Can Elevance's (ELV) Q3 Earnings Beat on Carelon Strength?
by Zacks Equity Research
The third-quarter results of Elevance (ELV) are likely to reflect strong rate adjustments and membership growth in the Health Benefits business.
Centene (CNC) Eyes Membership Growth With 2024 Expansion Plans
by Zacks Equity Research
Centene (CNC) declares the availability of a varied set of health plans across new counties in 2024. It, thereby, places intensified focus on growing its Medicare business.
Will UnitedHealth's (UNH) UnitedHealthcare Unit Aid Q3 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) third-quarter results are expected to benefit from an increase in UnitedHealthcare's Community & State revenues as well as the number of people it served.
Can High Medical Costs Affect UnitedHealth (UNH) Q3 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) third-quarter results are likely to reflect growth in memberships and premium levels.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
S&P 500 Logs Worst Month of 2023: 5 Stocks Still Up in ETF
by Sweta Killa
The S&P 500 witnessed its worst month of 2023, losing 5% in September. Fears of higher rates for a longer-than-expected period took the sheen away from stocks in the month.
Here's How Much You'd Have If You Invested $1000 in Centene a Decade Ago
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Why Centene (CNC) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Here's Why Centene (CNC) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain Centene (CNC) in Your Portfolio
by Zacks Equity Research
Strong growth in membership, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
5 HMO Stocks to Watch Amid Growing Premiums & Membership
by Debasmita Chatterjee
Expanding customer base, contract wins and a rapidly growing aging U.S. population will likely drive the performances of the Zacks Medical-HMO industry players. UNH, CI, HUM, CNC and MOH are poised to benefit from favorable industry trends.
Centene (CNC) Divests Circle Health Group, Optimizes Portfolio
by Zacks Equity Research
Centene (CNC) announces the sale of Circle Health Group to PureHealth in a bid to dispose of non-core assets and grow its core Managed Care business.